The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-08-18
DOI
10.3389/fimmu.2020.01951
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases
- (2019) Rossella Talotta et al. Immunotherapy
- Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
- (2019) Li Yan et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
- (2019) Whitney P. Kirschbrown et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Immunogenicity and Skin Clearance Recapture in Clinical Studies of Brodalumab
- (2019) Jerry Bagel et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Infliximab–Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies
- (2019) Haggai Bar-Yoseph et al. GASTROENTEROLOGY
- A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients
- (2019) Antonino Cassotta et al. NATURE MEDICINE
- Immunogenicity of pembrolizumab in patients with advanced tumors
- (2019) Marianne J. H. van Vugt et al. Journal for ImmunoTherapy of Cancer
- Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
- (2019) Jesús García-Foncillas et al. Frontiers in Oncology
- HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease
- (2019) Aze Wilson et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
- (2019) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
- (2019) Aleksejs Sazonovs et al. GASTROENTEROLOGY
- Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists
- (2019) Anna Vaisman-Mentesh et al. Frontiers in Immunology
- Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies
- (2018) Karin A van Schie et al. ANNALS OF THE RHEUMATIC DISEASES
- Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases
- (2018) Bella Ungar et al. Clinical Gastroenterology and Hepatology
- Belimumab: A Review in Systemic Lupus Erythematosus
- (2018) Hannah A. Blair et al. DRUGS
- Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
- (2018) Heejin Lim et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Functional interrogation and mining of natively paired human VH:VL antibody repertoires
- (2018) Bo Wang et al. NATURE BIOTECHNOLOGY
- Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study
- (2018) Qian Chen et al. PLoS One
- The Increasingly Human and Profitable Monoclonal Antibody Market
- (2018) António L. Grilo et al. TRENDS IN BIOTECHNOLOGY
- A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
- (2018) M. Fevzi Ozkaynak et al. Frontiers in Immunology
- Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab
- (2018) Anders H. Kverneland et al. OncoImmunology
- Clinical Pharmacology of Alemtuzumab, an Anti-CD52 Immunomodulator, in Multiple Sclerosis
- (2018) Zhaoyang Li et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins
- (2018) Qun Zhou et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
- (2018) Jocelyn Quistrebert et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti–TNF-α Antibodies after a Single Injection in Mice
- (2017) Christophe Arnoult et al. JOURNAL OF IMMUNOLOGY
- Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
- (2017) Nicky Dunn et al. Multiple Sclerosis Journal
- Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
- (2017) Mark H. Wilcox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antidrug Antibodies in Patients Treated with Alirocumab
- (2017) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity of Therapeutic Antibodies
- (2017) Karien Bloem et al. THERAPEUTIC DRUG MONITORING
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
- (2017) David Baker et al. JAMA Neurology
- Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
- (2017) Nicky Dunn et al. Multiple Sclerosis Journal
- Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects
- (2017) Jorge Máspero Therapeutic Advances in Respiratory Disease
- Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors
- (2017) Moustafa Hamze et al. Frontiers in Immunology
- The Immune Epitope Database and Analysis Resource in Epitope Discovery and Synthetic Vaccine Design
- (2017) Ward Fleri et al. Frontiers in Immunology
- Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria
- (2016) Peter Hillmen et al. AMERICAN JOURNAL OF HEMATOLOGY
- Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
- (2016) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn’s disease patients treated with infliximab
- (2016) B. Hernández-Breijo et al. BIOCHEMICAL PHARMACOLOGY
- Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions
- (2016) A. Vultaggio et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Design and engineering of deimmunized biotherapeutics
- (2016) Karl E Griswold et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors
- (2016) Shruti Agrawal et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
- (2016) Anette Karle et al. mAbs
- Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination
- (2016) Jiwon Lee et al. NATURE MEDICINE
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
- (2016) Emilie M.J. van Brummelen et al. ONCOLOGIST
- Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers
- (2016) Arun Rajan et al. Human Vaccines & Immunotherapeutics
- Evaluation of Multiple Immunoassay Technology Platforms to Select the Anti-Drug Antibody Assay Exhibiting the Most Appropriate Drug and Target Tolerance
- (2016) Justine Collet-Brose et al. Journal of Immunology Research
- Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products
- (2015) Liusong Yin et al. CELLULAR IMMUNOLOGY
- FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
- (2015) A. Deisseroth et al. CLINICAL CANCER RESEARCH
- A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays
- (2015) Jad Zoghbi et al. JOURNAL OF IMMUNOLOGICAL METHODS
- FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
- (2015) Michal Pyzik et al. JOURNAL OF IMMUNOLOGY
- Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
- (2015) Ulrich Mrowietz et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
- (2015) Shomron Ben-Horin et al. Expert Review of Gastroenterology & Hepatology
- The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
- (2015) Hsien-Yi Chiu et al. PLoS One
- Proteomic Identification of Monoclonal Antibodies from Serum
- (2014) Daniel R. Boutz et al. ANALYTICAL CHEMISTRY
- Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
- (2014) Stephane Paul et al. INFLAMMATORY BOWEL DISEASES
- The therapeutic monoclonal antibody market
- (2014) Dawn M Ecker et al. mAbs
- Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
- (2014) Nicole A. Doria-Rose et al. NATURE
- The promise and challenge of high-throughput sequencing of the antibody repertoire
- (2014) George Georgiou et al. NATURE BIOTECHNOLOGY
- What's fueling the biotech engine—2012 to 2013
- (2014) Saurabh (Rob) Aggarwal NATURE BIOTECHNOLOGY
- In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire
- (2014) Brandon J DeKosky et al. NATURE MEDICINE
- Identification and characterization of the constituent human serum antibodies elicited by vaccination
- (2014) Jason J. Lavinder et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drug allergens and food—the cetuximab and galactose-α-1,3-galactose story
- (2013) Emily A. Berg et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
- (2013) Vibha Jawa et al. CLINICAL IMMUNOLOGY
- Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma
- (2013) Laura Somerville et al. CURRENT MEDICAL RESEARCH AND OPINION
- High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire
- (2013) Brandon J DeKosky et al. NATURE BIOTECHNOLOGY
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
- (2013) Pauline A. van Schouwenburg et al. Nature Reviews Rheumatology
- Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response
- (2013) Y. Wine et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses
- (2013) Brian Baldo OncoImmunology
- Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
- (2012) Fabien B Vincent et al. ANNALS OF THE RHEUMATIC DISEASES
- The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
- (2012) Sandra Garcês et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity and autoimmunity during anti-TNF therapy
- (2012) F. Atzeni et al. AUTOIMMUNITY REVIEWS
- Immunogenicity of biological therapeutics
- (2012) Charlotte Krieckaert et al. CURRENT OPINION IN RHEUMATOLOGY
- Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease
- (2012) Suhrad G. Banugaria et al. GENETICS IN MEDICINE
- HLA-DM Constrains Epitope Selection in the Human CD4 T Cell Response to Vaccinia Virus by Favoring the Presentation of Peptides with Longer HLA-DM-Mediated Half-Lives
- (2012) L. Yin et al. JOURNAL OF IMMUNOLOGY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- A Survey of Applications of Biological Products for Drug Interference of Immunogenicity Assays
- (2012) Yow-Ming C. Wang et al. PHARMACEUTICAL RESEARCH
- Antibody isolation from immunized animals: comparison of phage display and antibody discovery via V gene repertoire mining
- (2012) I. Saggy et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Next generation deep sequencing and vaccine design: today and tomorrow
- (2012) Fabio Luciani et al. TRENDS IN BIOTECHNOLOGY
- Review article: loss of response to anti-TNF treatments in Crohn’s disease
- (2011) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Assessing Response and Loss of Response to Biological Therapies in IBD
- (2011) Henit Yanai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site
- (2011) M M Stickler et al. GENES AND IMMUNITY
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists
- (2011) Christophe Lallemand et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Differential effect of drug interference in immunogenicity assays
- (2011) Margreet H. Hart et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Coupling of Aggregation and Immunogenicity in Biotherapeutics: T- and B-Cell Immune Epitopes May Contain Aggregation-Prone Regions
- (2011) Sandeep Kumar et al. PHARMACEUTICAL RESEARCH
- Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing
- (2011) X. Wu et al. SCIENCE
- The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful
- (2010) S. Ben-Horin et al. GUT
- Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics
- (2010) Suzanna Tatarewicz et al. JOURNAL OF IMMUNOLOGICAL METHODS
- The immunogenicity of humanized and fully human antibodies
- (2010) Fiona A. Harding et al. mAbs
- Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells
- (2010) Sai T Reddy et al. NATURE BIOTECHNOLOGY
- The safety and side effects of monoclonal antibodies
- (2010) Trevor T. Hansel et al. NATURE REVIEWS DRUG DISCOVERY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive assessment of T-cell receptor -chain diversity in T cells
- (2009) H. S. Robins et al. BLOOD
- The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells
- (2009) M. Taillardet et al. BLOOD
- Immunogenicity of rituximab in patients with severe pemphigus
- (2009) Enno Schmidt et al. CLINICAL IMMUNOLOGY
- T-Independent Antibody Responses to T-Dependent Antigens: A Novel Follicular Dendritic Cell-Dependent Activity
- (2009) M. E. M. El Shikh et al. JOURNAL OF IMMUNOLOGY
- Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire
- (2009) J. Glanville et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"
- (2008) A. S. De Groot et al. BLOOD
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
- (2008) Christine H. Chung et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started